Acrux Limited (ACR) Fair Value & Analysis
Healthcare · AU · Market cap A$6.3M
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 5 days ago
Share price +40.0% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0084 – A$0.0195 · the A$0.0130 price screens above the A$0.0100 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Acrux Limited (ACR) currently trades at A$0.0130, while our model-based Fair Value estimate is A$0.0100 — implying the stock looks roughly 23.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Acrux Limited generated revenue of A$2.8M at a net margin of -83.8%. Net debt stands at A$2.8M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Acrux Limited reported revenue of A$1.2M in FY2025 versus A$1.3M in FY2021, a compound −2.9%/yr. Reported net income was −A$5.9M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $303.64 | $110.31 | -64% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Acrux Limited (ACR) undervalued?
What is the fair value of ACR?
What is the quality score of ACR?
What is the revenue of Acrux Limited (ACR)?
What is the net profit margin of ACR?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.